When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
On May 15, Oramed announced that their partner in China had completed a positive phase 3 oral insulin trial in China and had submitted an application to the Chinese regulator.
In the same PR, Oramed announced their post-hoc analysis of their failed US p3 trial and said that they found positive data in subgroups of trial participants.
Oramed is "exploring ways to move forward with its oral insulin product". Previously, Oramed expected to discontinue its oral insulin clinical activities for T2D [Type2 Diabetics].